Arcus Biosciences (RCUS) Operating Income (2017 - 2026)

Arcus Biosciences' Operating Income history runs 10 years deep, the most recent figure standing at -$134.0 million for Q1 2026.

• In Q1 2026, Operating Income fell 9.84% year-over-year to -$134.0 million; the TTM figure through Mar 2026 stood at -$398.0 million (up 8.72% YoY), while the FY2025 annual figure was -$386.0 million, down 16.97% from the prior year.
• Operating Income was -$134.0 million for Q1 2026 at Arcus Biosciences, down from -$114.0 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$8.0 million in Q2 2025 to a low of -$142.0 million in Q3 2025.
• Historically, Operating Income has averaged -$86.5 million across 5 years, with a median of -$86.0 million in 2023.
• Biggest YoY gain for Operating Income was 92.45% in 2025; the steepest drop was 662.5% in 2025.
• A 5-year view of Operating Income shows it stood at -$74.0 million in 2022, then slipped by 22.97% to -$91.0 million in 2023, then dropped by 13.19% to -$103.0 million in 2024, then declined by 10.68% to -$114.0 million in 2025, then slipped by 17.54% to -$134.0 million in 2026.
• The last three Operating Income figures came in at -$134.0 million (Q1 2026), -$114.0 million (Q4 2025), and -$142.0 million (Q3 2025), per Business Quant data.